<DOC>
	<DOCNO>NCT00275002</DOCNO>
	<brief_summary>This phase II trial study well give O6-benzylguanine together temozolomide work treat young patient recurrent progressive glioma brain stem tumor . Drugs use chemotherapy , O6-benzylguanine temozolomide , work different way stop growth tumor cell , either kill cell stop divide . O6-benzylguanine may help temozolomide work well make tumor cell sensitive drug . Giving one drug ( combination chemotherapy ) may kill tumor cell .</brief_summary>
	<brief_title>O6-Benzylguanine Temozolomide Treating Young Patients With Recurrent Progressive Gliomas Brain Stem Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine sustain objective response rate combination O6-benzylguanine temozolomide pediatric patient recurrent progressive high-grade glioma brain stem tumor . SECONDARY OBJECTIVES : I . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients stratify accord tumor type ( high-grade glioma v brain stem tumor ) . Patients receive O6-benzylguanine IV 1 hour follow oral temozolomide day 1-5 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow early 30 day follow discontinuation therapy initiation additional anti-cancer therapy death . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>INCLUSION CRITERIA Tumor : Participants must highgrade glioma ( include e.g . histologically confirm anaplastic astrocytoma , glioblastoma multiforme , anaplastic oligodendroglioma , anaplastic ganglioma , gliosarcoma ) brainstem tumor ( histologic confirmation waive ) documentation disease recurrence progression treatment standard therapy . Participants must bidimensionally measurable disease , define least 1 lesion measure ≥ 2 dimension Age : 21 year age less Performance status : Karnofsky 60100 % ( patient &gt; 16 year age ) Lansky 60100 % ( patient ≤ 16 year age ) Life expectancy : Not specify Hematopoietic : Must adequate bone marrow function define absolute neutrophil count &gt; 1,500/mm^3 , platelet count &gt; 100,000/mm^3 ( unsupported ) , hemoglobin &gt; 8 g/dL ( may support ) , absolute lymphocyte count ≥ 500/mm^3 Hepatic : Must SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) , bilirubin ≤ 1.5 time ULN , overt hepatic disease Renal : Participants must creatinine clearance ≥ 60 mL/min creatinine base age follow : great 0.8 mg/dL ( patient ≤ 5 year age ) , great 1.0 mg/dL ( patient 6 10 year age ) , great 1.2 mg/dL ( patient 11 15 year age ) , great 1.5 mg/dL ( patient &gt; 15 year age ) . There must overt renal disease Cardiovascular : Must overt cardiac disease Pulmonary : Must overt pulmonary disease Other : Female participant childbearing potential must negative pregnancy test prior study registration , must avoid breastfeeding . Female male participant childbearing childfathering potential must use effective contraception Bone Marrow Transplant : Must least 6 month since prior allogeneic bone marrow transplantation least 3 month since prior autologous bone marrow stem cell transplantation Growth Factors : Must least 2 week since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , erythropoietin ) Prior Chemotherapy : Must receive last dose myelosuppressive anticancer chemotherapy ≥ 3 week prior study registration ≥ 6 week nitrosoureas . Must receive last dose nonmyelosuppressive investigational agent anticancer drug ≥ 7 day prior study registration . Participants receive prior temozolomide eligible Concurrent Endocrine Therapy : Concurrent corticosteroid therapy allow Prior Radiotherapy : Must receive last fraction craniospinal irradiation local irradiation primary tumor ≥ 12 week prior study registration Prior TherapyOther : Must recover prior therapy EXCLUSION CRITERIA Must history severe toxicity ( ≥ grade 3 ) associate temozolomide Must receive concurrent anticancer investigational therapy Must history hypersensitivity dacarbazine , temozolomide , polyethylene glycol ( PEG ) Must uncontrolled significant systemic illness include infection , overt renal , hepatic , cardiac , pulmonary disease Must HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>recurrent childhood brain tumor</keyword>
</DOC>